Newsletter · 2026-07-31 · Ashutosh Agarwal

Medicare Covers Weight Loss Drugs as Insurers Quietly Win - The Healthcare Pulse - Week of July 31, 2026

Healthcare podcast-intelligence brief for the week of July 31, 2026. Medicare's new BRIDGE pilot will help older Americans pay for GLP-1 weight-loss drugs at $50 a month, health insurers repaired margins by shedding members while hospitals absorbed the newly uninsured, Intuitive Surgical's 40% crash became the week's big single-stock debate, and the FDA came out swinging against small biotechs Capricor and Replimune.

The Healthcare Pulse

Week of July 31, 2026: Medicare Covers Weight Loss Drugs as Insurers Quietly Win

This Week at a Glance

If last week the obesity-drug story turned into a courtroom brawl, this week the conversation moved somewhere less dramatic but arguably more important for investors: money. Who pays for these drugs, who profits from insuring people, and who eats the cost when Americans quietly lose their health coverage. It was, in short, a week about the plumbing of the healthcare system, and the plumbing is under real strain.

The single loudest new development was a change to Medicare. For the first time, the government will help older Americans pay for weight-loss drugs, through a pilot program called BRIDGE that caps the out-of-pocket cost at $50 a month. That sounds like a straightforward win for drugmakers, but the podcast conversation this week was full of caveats: the pilot may last only 18 months, roughly a third of patients stop taking these drugs within a year, and most people regain the weight when they quit. So the question that ran under everything was whether the obesity boom is a permanent new market or a revolving door.

Six threads ran through the week's podcasts and news:

• Medicare finally covers weight-loss drugs, with an asterisk. The new $50-a-month BRIDGE pilot could reach up to 30 million Medicare members. But doctors on air were openly skeptical it will last, and warned that people who lose the coverage will simply regain the weight.
• The insurers are quietly winning; the hospitals are quietly bleeding. Second-quarter results showed health insurers repairing their profit margins by walking away from unprofitable customers: Humana alone is dropping 600,000 members. Hospitals, meanwhile, are absorbing a wave of newly uninsured patients they can't turn away and can't bill.
• Intuitive Surgical's 40% crash became the week's big single-stock debate. The maker of the da Vinci surgical robot reported a genuinely strong quarter, yet the stock has been cut nearly in half. Investors spent the week arguing whether that's a bargain or a warning about the whole sector.
• Washington's squeeze got more concrete. Medicare drug-plan premiums are set to jump sharply, a 100% tariff on imported generic medicines is now on the calendar (though not until 2028), and a new FDA committee vote nudged a batch of trendy "peptides" one step closer to legitimacy.
• The FDA is picking fights again. After a period of looking more flexible, regulators came out swinging against two small biotechs, Capricor and Replimune, in a way one host called genuinely stunning.
• The mid-size biotechs have become buyers. A European drugmaker, Argenx, did its first-ever acquisition, and the week's discussion was about how a whole new tier of companies is now competing with Big Pharma to buy the next breakthrough.

A note on this week's mix: obesity/GLP-1 economics, health-insurance and drug-pricing policy, and biotech dealmaking/FDA drama produced the richest podcast material. Direct, stock-by-stock investor debate on the big pharma names reporting earnings (Pfizer, Merck, Amgen, Bristol Myers, Gilead) was again thin on podcasts this week (even searching specifically for it turned up little), so those sections lean on earnings releases and analyst notes, and we flag it where it matters.

The People Driving the Conversation

Jakob Emerson of Becker's, on why the insurers are fine and the hospitals are not. The clearest explanation of the quarter came from healthcare journalist Jakob Emerson on the Becker's Healthcare Podcast (July 29), walking host Scott Becker through the second-quarter results of the big insurers and hospital chains. His core point: when the enhanced Affordable Care Act subsidies expired at the end of last year, insurers saw it coming and hospitals got stuck with the bill. Insurers "filed two different sets of rates with states," he explained, so they could raise premiums the moment subsidies lapsed, betting that healthier people would drop coverage rather than pay up. That is exactly what happened, but worse than hospitals expected: a chain like HCA had assumed that of the people priced out, "around 80% to 85%" would go uninsured and 15% would find other coverage, but "it ended up being that almost 100% of those people ended up not getting coverage elsewhere." The result, Emerson said, is that HCA now expects the hit to its payer mix to run "somewhere between a billion and 1.2 billion over the course of this entire year," up from an earlier $600–900 million estimate, roughly a $400 million swing. His reality check for anyone tempted to feel sorry for the hospitals: exchange patients are "only about 5.5% of [Tenet's] overall revenue," and there are only "19 million ACA exchange enrollees" versus "over 100 million people enrolled in employer-based plans." On the insurer side, he described a "multi-year rebuild" where everyone is chasing margin by shedding customers: Centene "had over a $250 million loss in the same quarter last year… and then they recorded over a billion dollars in profit this year"; Humana "just announced today they're going to drop 600,000 members through targeted exits." His summary of the era: it's a reversal of "the decade before this, which was growth… at all costs."

Nick and Kasey Rossolillo, on whether Intuitive Surgical's crash is a gift. On the Chip Stock Investor Podcast (July 28), the husband-and-wife team took apart the year's most jarring healthcare chart: Intuitive Surgical ($ISRG), the dominant maker of robotic surgery systems, down to $345, "off well over 40% from its early 2025 and 2026 highs touching nearly $600." The strange part, they noted, is that the business is thriving: da Vinci procedures up 15% year-over-year, an installed base of nearly 12,000 systems, revenue up 19% to $2.9 billion, gross margin back to 70%, and a fortress balance sheet of "$8.6 billion in cash and equivalents, no debt." So why the crash? They pointed to comments from Intuitive's own executives. CFO Jamie Samath told analysts that "based on customer feedback, we believe there's a modest adverse impact to Q2 U.S. da Vinci procedure growth from those patients impacted by the expiration of subsidies for ACA enhanced premiums." CEO David Rosa wouldn't give a precise number, saying only that "a significant portion of the business is private pay or commercial insurance," with Medicare and Medicaid smaller slices. The hosts laid out three explanations for the sell-off, and refused to pick just one: fear of "a healthcare bubble and growing cracks in the U.S. healthcare foundation"; a belief that Intuitive will keep compounding but at a slower ~15% rather than a premium rate; or simply "a $1 trillion market rotation" out of healthcare and into AI and reshoring plays. Their verdict was studiously balanced: "we preach radical moderation… it's somewhere in the middle of all of these three scenarios."

Dr. Robert Pearl, on Medicare's weight-loss experiment and "the patient revolt ahead." On Medicine: The Truth (July 29), physician and author Dr. Robert Pearl walked through the new Medicare BRIDGE pilot in unusual detail and was frank about its limits. The upside is real: "For the first time, Medicare will cover GLP-1 medications for weight loss," at "only $50 a month… about 80% less than the price that individuals who don't use their insurance pay." But he stressed the fine print. It is "a pilot program… isn't guaranteed to last after 18 months," it is run by Humana and sits outside the normal Medicare Part D system, and it requires patients to hit specific weight and health thresholds (a body mass index over 35 if otherwise healthy, lower if they have heart disease or diabetes). The government will pay "around $245 a month" for the drugs. Of Medicare's 70 million members, he said, "around 40%, or close to 30 million individuals, appear to meet the coverage criteria," though 16 million already get the drugs through Part D for diabetes or heart disease. His sharpest warning was about durability: "if the program is successful, but the funding isn't continued after 18 months, enrollees are likely to regain the weight, and the pilot will have been a failure." He also put a number on how mainstream these drugs have become: "an estimated 15% of all Americans have already tried a GLP-1, and 11% report currently using them. That's nearly one in eight."

Harith Rajagopalan of Fractyl Health, on building a market for people who quit GLP-1s. On the DeviceTalks Weekly Podcast (July 24), Fractyl Health CEO Harith Rajagopalan made the case for an idea that only exists because the obesity drugs work so well: a one-time procedure to help people keep weight off after they stop taking the drugs. Fractyl's approach targets the lining of the duodenum (the first stretch of the small intestine), which Rajagopalan argued is "a key metabolic signaling organ" and the "very first change that takes place in the body that's causing all of the downstream consequences associated with obesity." The company's device uses a catheter threaded down through the mouth to ablate (deliberately destroy) that overgrown lining so the body can regrow a healthy one. His framing of the opportunity: today's options are inadequate in two ways: drugs and diets "work as long as you take them" but don't "fix the root cause," while bariatric surgery is "remarkably effective, but doesn't have a safety and scalability profile" for the "100 million people in the United States with obesity." Fractyl's bet is to sit in between. It is an early, unproven idea, but it captures a genuine emerging investment theme: hardware and procedures aimed squarely at the "morning after" of the GLP-1 boom.

Dr. Shawn Tassone, on what the FDA's "peptide vote" actually did. On Confessions of a Male Gynecologist (July 30), Dr. Shawn Tassone cut through a wave of online hype about the FDA supposedly "approving peptides." What really happened, he explained, is that "on July 23rd and 24th of 2026, the FDA Pharmacy Compounding Advisory Committee voted to recommend six peptides for inclusion on the Section 503A bulk list," a list of ingredients that compounding pharmacies can legally prepare. The compounds included the popular healing peptide BPC-157, plus TB-500, KPV, MOTS-c, Epitalen and CEMAX. His repeated caution: "It was not FDA approval of a finished drug," the vote was close ("an 8 to 6 vote with one abstention"), and "the recommendations aren't binding." His honest bottom line on the science, "unproven doesn't mean disproven. It means the burden of proof has not yet been met," is a useful lens for a whole category of wellness products now edging toward the mainstream.

The Key Debates

Debate 1: Are the health insurers a bargain at the bottom of the cycle, or a value trap? This was the most fully argued investment debate of the week, spanning both podcasts and analyst notes. The bull case is that the pain in Medicare Advantage (the privately run version of Medicare) is now behind the industry, and margins are climbing back. On the Becker's podcast (July 29), Jakob Emerson described exactly that recovery in progress: Humana said "their individual Medicare Advantage pre-tax margin should double this year," and UnitedHealth, Elevance and others are all "trying to rebuild margins… mostly going into next year" by exiting weak markets and shedding expensive members. On the Street, this view has real backers: Evercore ISI's Elizabeth Anderson initiated UnitedHealth ($UNH) at Outperform, and Goldman Sachs added it to its U.S. Conviction List with a $435 target, arguing the underwriting cycle is bottoming (first-quarter medical cost ratio improved 90 basis points to 84%) (per barchart.com, 247wallst.com).

The bear case is that the margin damage is structural, not cyclical. Skeptics point to roughly 340 basis points of margin erosion over two years driven by an aging population, the fact that UnitedHealth is shedding more than 3 million members, and a Department of Justice probe into its Optum unit that carries divestiture risk (per 247wallst.com, phemex.com). And there's a fresh overhang: the Wall Street Journal reported that Medicare drug-plan (Part D) premiums are "set to increase sharply," with the Trump administration cutting Part D subsidy spending by roughly 40% (thefly, 2026-07-28; https://www.wsj.com/health/healthcare/medicare-part-d-drug-plan-premiums-set-to-rise-16ef919c). Regulators are letting the "Part D Premium Stabilization Demonstration" expire at the end of 2026, and the average monthly bid amount for 2027 is up about 24% to $296.05 (per managedhealthcareexecutive.com, cms.gov). The through-line, as Emerson put it, is that the insurers are protecting themselves: "it's a loss to the consumer, but the insurers seem to do OK." Whether that resilience is a durable moat or a slow-motion demographic squeeze is the crux of the debate.

Debate 2: Intuitive Surgical, buy the 40% dip, or heed the warning? The Chip Stock Investor hosts (July 28) framed this as cleanly as anyone. On the numbers, Intuitive looks like a wonderful business getting cheaper: 15% procedure growth, 19% revenue growth, a pristine balance sheet, and a near-monopoly in robotic surgery that even a newly cleared competitor hasn't dented. The bull reads the sell-off as an overreaction to a "modest" and temporary ACA-related dip in procedures, and to a broad rotation out of healthcare, meaning the growth story is intact and the stock is now merely priced for a still-healthy ~15% annual earnings growth over a decade. The bear reads the same facts as an early crack: if fewer Americans carry insurance, hospitals eat more bad debt, and "when hospitals have more debt, they are probably not in the market for nearly $2 million machines." On that view, the multiple compression is the market correctly re-rating a stock that had simply gotten too expensive for a world where U.S. healthcare utilization may be peaking. Notably, Intuitive's own 2026 guidance (13.5%–15.5% procedure growth) already "bakes in" the ACA headwind, China pricing pressure, European capital constraints, and even GLP-1 drugs reducing weight-loss surgeries, so the debate is really about what comes after this year.

Debate 3: How tough should the FDA be on small biotechs with imperfect data? Two advisory-committee meetings this week revived a fight everyone thought was easing. On both the BioSpace Weekly (July 29) and STAT's The Readout Loud (July 30), the story was the same: the FDA came out unexpectedly hard against two companies. For Capricor and its Duchenne muscular dystrophy cell therapy, "the FDA released their briefing documents… and they revealed that they disagreed with Capricor's claims that a phase three trial met its primary endpoint," a move a BioSpace editor called genuinely stunning: "I can't think of a time that I've ever seen this." Capricor's CEO Linda Marban expressed hope the panel would "be able to see through the statistical analysis plans and not turn this into something mathematical," and instead judge the therapy on its effectiveness. For Replimune and its melanoma immunotherapy RP1, the FDA argued the company's single-arm study "is not interpretable" and "potentially not sufficient to support approval." Replimune countered that a traditional randomized trial "would have been unethical in this population," and pointed out that "Iovance, Merck, and Bristol-Myers Squibb have actually received approvals in melanoma based on single-arm trials." The larger debate, how much proof is enough, and whether the FDA's recent whiplash between flexibility and rigor is good governance or chaos, has direct read-through for every small drug developer hoping for a faster path to market. (For context: the meetings were set for July 29 and 30; the FDA usually, but not always, follows its committees' advice.)

Hot Topics Under Debate

• The Medicare BRIDGE weight-loss pilot (the week's marquee policy event). Beyond the $50 copay, the details matter for anyone modeling the obesity market. As Dr. Robert Pearl detailed on Medicine: The Truth (July 29), the government pays about $245/month, Humana administers it, and it lives outside standard Part D, so the ~$600/year a patient pays doesn't count toward their normal drug deductible or out-of-pocket cap. That's a real barrier: Pearl cited Kaiser data showing "half of the current enrollees live on incomes of $43,000 a year," and for many "$600 a year may prove prohibitive." Patients get four choices (Lilly's Zepbound shot or its Fondeo pill, or Novo's Wegovy in shot or pill form) with injectables delivering "somewhere between a 15% and 20% weight loss on average" and pills "between 10% and 15%." The whole thing is a giant, time-limited experiment in whether cheaper access actually improves health before the funding potentially disappears in 18 months.
• Bristol Myers Squibb's blowout quarter, the one big-pharma print that landed early. Bristol Myers ($BMY) reported before the week's earnings cluster and beat handily: adjusted earnings of $2.04 per share versus $1.60 expected, revenue of $12.97 billion versus $11.74 billion, and its "Growth Portfolio" up 15%. Crucially, it raised full-year guidance, adjusted EPS to $6.75–$7.00 (from $6.05–$6.35) and revenue to $49–50 billion (from $46–47.5 billion) (thefly, 2026-07-30). It's a useful counterweight to the sector's gloom: at least one major drugmaker is executing well as its older blockbusters age out.
• Johnson & Johnson trades near-term earnings for dealmaking. J&J ($JNJ) cut its 2026 adjusted EPS outlook to $10.86–$11.01 (from $11.50–$11.65) after closing the Firefly Bio acquisition and signing a collaboration with Sail Biomedicines; the two deals dilute this year's earnings by about $0.64 and next year's by roughly $1.36 (thefly, 2026-07-29). Separately, Argus raised its price target to $300, Buy, citing the comprehensive resolution of J&J's talc litigation, and J&J won FDA clearance for its Ottava surgical robot, a direct, if still distant, challenge to Intuitive (thefly, 2026-07-27/29). The read: J&J is spending near-term profit to buy future growth, and clearing legal overhangs along the way.
• The generics tariff, a slow fuse with a real price tag. On the Daybreak podcast (July 28), hosts from The Ken explained why Indian pharma stocks wobbled at a tariff that doesn't bite for two years. President Trump said tariffs on imported generic medicines "would eventually hit 100%," specifically on August 1, 2028, rising to 200% in 2029 if companies haven't moved manufacturing to the U.S. The stakes: India supplies "nearly 50% of all generic medicines consumed in America," worth "$8 to $9 billion" a year, and generics are "90% of prescriptions" but only "13% of drug spending." A Health Affairs Scholar study cited on the show estimated a 100% tariff would raise generic prices about 30%, or "roughly $21" on a typical $70 prescription, hitting staples like birth control and antidepressants. The blunt industry response came from Dr. Reddy's CEO Erez Israeli: "We are not going to invest because of tariffs. We are going to invest because it's good business." Analysts on the show argued reshoring generics in two years is unrealistic: building the ecosystem "would take at least five years," and Indian manufacturing costs are "40 to 60% lower," so even with tariffs the math may not favor moving. (This is separate from the up-to-100% Section 232 duties looming on patented drugs and ingredients, which could begin biting far sooner.)
• Merck's oral cholesterol pill, a potential answer to the Keytruda cliff. Merck ($MRK) secured approval of enlicitide, described as the first oral PCSK9 inhibitor for high cholesterol, a pill version of a drug class that until now required injections, and a potential top-line driver as Merck's cancer blockbuster Keytruda approaches the end of its patent life (per Life Science Daily). Merck reports Q2 on August 4; Barclays lifted its target to $150, Overweight (thefly, 2026-07-29).
• Pfizer's pipeline quietly delivered. Ahead of its August 4 report, Pfizer ($PFE) got FDA Priority Review for a prostate-cancer combination (Talzenna plus Xtandi), with a decision expected in the last quarter of 2026; its updated COVID vaccine was authorized across the EU; and its drug Litfulo hit its goals in two late-stage trials for vitiligo, a skin-pigment disorder (thefly, 2026-07-22/29/30). Pfizer's ~$10 billion purchase of Metsera also keeps getting cited as part of a broader Big Pharma buying spree.

Emerging Themes to Watch

• The "morning after" of the obesity boom is becoming its own investment category. The central tension in the GLP-1 story is no longer whether the drugs work, it's that most people don't stay on them. Broad commercial data suggests only about a third of patients remain on treatment after a year, and doctors keep warning that stopping means regaining the weight. That single fact is spawning new businesses: Fractyl's one-time gut procedure (DeviceTalks, July 24) is the clearest example, aiming to help former users keep weight off without staying on the drugs forever. Expect more devices, maintenance therapies, and services pitched at the enormous population that will cycle off these medicines.
• A new tier of biotech buyers has emerged. On BioCentury This Week (July 28), the editors dug into Argenx buying Forte Biosciences for about $2.2 billion ($77/share), the European drugmaker's first-ever acquisition, funded by the success of its blockbuster Vivgart, which did "$1.5 billion in revenue" last quarter alone. The bigger point was structural: it's no longer just Big Pharma doing the buying. "Vertex just made a $10 billion deal" (for Crinetics), GenMab "paid $8 billion for Mirus," and Incyte bought Vega for over a billion. For sellers, that means more bidders and better prices; for the giants, it means competition for the best assets is coming from companies a fraction their size. One editor noted that in real deal talks, pharma is now "not only looking at their $100 billion-plus peers" but at this rising mid-tier.
• Deal-driven rare-disease platforms. On RARECast (July 30), Chiesi's Giacomo Chiesi described building a global rare-disease business by stacking technologies through deals: a 2025 CRISPR gene-editing partnership with Arbor Biotechnologies for a kidney-stone disorder, and a $1.9 billion acquisition of Calvista Therapeutics in April 2026 for an oral therapy for hereditary angioedema. The strategy, owning "four different technology platforms" from small molecules to gene editing, echoes the broader industry bet that no single tool wins, so breadth is the safer play.
• AI moves from hype to plumbing in drug research. The genuinely healthcare-specific AI conversation this week was less about miracle cures and more about workflow. On Discovery Matters (July 30), pharma executive Joe Luminello argued that healthcare's "10 to 12 year drug development timeline" creates "paralysis by inundation" when you bolt AI onto it, and that today's AI is good at "narrow tasks" (handling FDA submissions, marketing) rather than true general intelligence, so it needs "human contextual judgment" alongside it. Even the trade press is changing: BioCentury (July 28) launched an AI tool that lets subscribers query its archive through chatbots. Broader web coverage this week cited claims that AI-designed drugs are showing 80–90% success rates in early (Phase 1) trials, and that frontier AI firms are moving into biology (Anthropic reportedly acquired Coefficient Bio), worth watching, but still early and lightly verified. (A caveat for readers: many "AI in healthcare" podcasts this week were really general AI-industry shows with only a passing healthcare mention, so genuine sector-specific signal was thinner than the volume suggests.)
• The FDA's leadership turbulence is now affecting real decisions. The Capricor and Replimune fights (BioSpace/The Readout Loud, July 29–30) trace back to upheaval at the agency: canceled meetings, departed regulators, and a return of advisory panels while the FDA is "still trying to staff back up." The FDA also resumed publishing Complete Response Letters (the rejection notices it sends drugmakers), issuing 14 in one batch. Add Sarepta naming a new CEO, Michael Severino, as it works through its own safety saga, and the picture is of a regulatory environment where process risk, not just data risk, is back on the table for small-cap biotech.

Stocks on the Radar

Direction reflects the tone of this week's podcast and news commentary, not a formal rating or recommendation.

Upcoming Catalysts (next ~2 weeks, through ~Aug 14)

Big-pharma Q2 earnings, a dense cluster (all dates confirmed):

• July 31 (before open): AbbVie (ABBV), reporting today
• Aug 4: Pfizer (PFE), Merck (MRK, before open), Amgen (AMGN, after close), Gilead (GILD, after close)
• Aug 5: Eli Lilly (LLY), the most-watched print of the group, for any read on the obesity franchise and the Medicare BRIDGE opportunity

(Already reported this window: Bristol Myers Jul 30; Johnson & Johnson Jul 15; UnitedHealth Jul 16, those next report in October.)

FDA and regulatory:

• July 29 (occurred): Capricor (CAPR) FDA advisory committee on its Duchenne muscular dystrophy cell therapy, watch for the outcome and any FDA decision to follow
• July 30 (occurred): Replimune (REPL) FDA advisory committee on RP1 in melanoma
• Next week (per the peptide-vote coverage): the FDA is expected to weigh the Pharmacy Compounding Advisory Committee's July 23–24 recommendation on six peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalen, CEMAX) for the Section 503A compounding list, a non-binding advisory step, not drug approval
• Q4 2026 (on the horizon): Pfizer's Talzenna+Xtandi prostate-cancer decision (Priority Review granted)
• Watch the calendar: Section 232 tariff duties on patented drugs and ingredients (up to 100%) are reported to potentially begin biting as early as late summer/fall 2026; the 100% generics tariff is dated to 2028

Data gap flagged honestly: no specific PDUFA dates or major investment conferences for the covered large-cap names landed cleanly inside the Aug 1–14 window in this week's sources, beyond the earnings cluster above.

The Bottom Line

This was a week that rewarded looking past the headlines. The flashy news (Medicare covering weight-loss drugs) is real and could eventually reach 30 million people, but the doctors closest to it spent their airtime on why it might not stick: an 18-month pilot, patients who quit within a year, and a $600 annual cost that could still price out the people it's meant to help. The obesity trade is maturing from "the drugs work" into the far harder question of "who stays on them, and who pays." That is why an odd little idea like Fractyl's (a procedure for people who've already quit) suddenly makes sense as an investment theme.

Underneath that sat a clearer and colder story about the financial plumbing of American healthcare. The insurers are repairing their profits the only way they can in a tough environment, by shedding customers, and the hospitals are left holding a growing bill for people who've lost coverage but still show up sick. Intuitive Surgical's 40% crash, despite a genuinely great quarter, is the market trying to price exactly that risk: if Americans use the healthcare system less because they can't afford it, even the best businesses in the sector feel it. Whether that's a temporary air pocket or a structural shift is the single most important debate for healthcare investors right now, and this week didn't settle it.

And around the edges, the machinery of the industry kept grinding: the FDA rediscovered its appetite for a fight, a new class of mid-size biotechs joined the buying spree, and Washington laid down markers on tariffs and drug prices that won't fully bite for years but are already moving stocks. With a wall of pharma earnings landing over the next five days, capped by Eli Lilly on August 5, the coming week will test which of these companies are on the right side of the line between a differentiated product with pricing power, and a business that simply rises and falls with how often Americans can afford to use the system.